Literature DB >> 15153447

Implication of the INK4a/ARF locus in gastroenteropancreatic neuroendocrine tumorigenesis.

Babette Simon1, Nikolaus Lubomierski.   

Abstract

The INK4a/ARF locus on chromosome 9p21 is one of the important defenses against tumor development and engages both the Rb and the p53 tumor suppressor pathways through its capacity to encode two distinct proteins, p16(INK4a) and p14(ARF). Despite controversial reports, the body of present data suggests that tumor suppressors p16(INK4a) and p14(ARF) are targets of in-activation in GEP-NETs. Moreover, tumor type-specific aberrant p16(INK4a) silencing appears to be associated with advanced tumor stage and may function as a predictor of patients' outcome after surgical resection. Since conventional histological and biochemical assessment are limited with respect to predicting GEP-NET behavior or outcome, methylation profiles including INK4a/ARF might offer a tool to refine future diagnosis and therapeutic management of GEP-NET patients.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15153447     DOI: 10.1196/annals.1294.033

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  9 in total

1.  Interaction among Rb/p16, Rb/E2F1 and HDAC1 proteins in gallbladder carcinoma.

Authors:  Xin Wang; Kai Huang; Lining Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-12-29

Review 2.  Towards a new classification of gastroenteropancreatic neuroendocrine neoplasms.

Authors:  Mark Kidd; Irvin Modlin; Kjell Öberg
Journal:  Nat Rev Clin Oncol       Date:  2016-06-07       Impact factor: 66.675

3.  RABL6A promotes G1-S phase progression and pancreatic neuroendocrine tumor cell proliferation in an Rb1-dependent manner.

Authors:  Jussara Hagen; Viviane P Muniz; Kelly C Falls; Sara M Reed; Agshin F Taghiyev; Frederick W Quelle; Francoise A Gourronc; Aloysius J Klingelhutz; Heather J Major; Ryan W Askeland; Scott K Sherman; Thomas M O'Dorisio; Andrew M Bellizzi; James R Howe; Benjamin W Darbro; Dawn E Quelle
Journal:  Cancer Res       Date:  2014-10-01       Impact factor: 12.701

Review 4.  Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets.

Authors:  Chandra K Maharjan; Po Hien Ear; Catherine G Tran; James R Howe; Chandrikha Chandrasekharan; Dawn E Quelle
Journal:  Cancers (Basel)       Date:  2021-10-12       Impact factor: 6.639

5.  Ribociclib and everolimus in well-differentiated foregut neuroendocrine tumors.

Authors:  Nitya Raj; Youyun Zheng; Haley Hauser; Joanne Chou; Johnathan Rafailov; Jad Bou-Ayache; Peter Sawan; Jamie Chaft; Jennifer Chan; Kimberly Perez; Charles Rudin; Laura Tang; Diane Reidy-Lagunes
Journal:  Endocr Relat Cancer       Date:  2021-04       Impact factor: 5.900

Review 6.  Clinicopathological Significance of CDKN2A Promoter Hypermethylation Frequency with Pancreatic Cancer.

Authors:  Bo Tang; Yang Li; Guangying Qi; Shengguang Yuan; Zhenran Wang; Shuiping Yu; Bo Li; Songqing He
Journal:  Sci Rep       Date:  2015-09-04       Impact factor: 4.379

7.  Prognostic impact of p16 and p21 on gastroenteropancreatic neuroendocrine tumors.

Authors:  Shuzheng Liu; Yuxi Chang; Jie Ma; Xu Li; Xiaohong Li; Jinhu Fan; Rong Huang; Guangcai Duan; Xibin Sun
Journal:  Oncol Lett       Date:  2013-10-09       Impact factor: 2.967

8.  p53 and p16Ink4a/p19Arf Loss Promotes Different Pancreatic Tumor Types from PyMT-Expressing Progenitor Cells.

Authors:  Stephanie Azzopardi; Sharon Pang; David S Klimstra; Yi-Chieh Nancy Du
Journal:  Neoplasia       Date:  2016-09-21       Impact factor: 5.715

9.  Gastrin: From Physiology to Gastrointestinal Malignancies.

Authors:  Suzann Duan; Karen Rico; Juanita L Merchant
Journal:  Function (Oxf)       Date:  2021-11-26
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.